Latest news

Debiopharm Group™ announces additional phase I clinical trial evaluating Debio 1143 combined with chemotherapies for patients with selected solid malignancies

Financement de Bourses d’excellence Debiopharm à l’EPFL et création de la ‘Debiopharm academy’

Cenix BioScience and Debiopharm Group™ collaborate to identify predictive biomarkers

Oncotest GmbH and Debiopharm Group™ announce a successful partnership in the identification of biomarker candidates

Debiopharm Group™ to support Ascepion in the development of Debio 1144 for the treatment of Chinese cancer patients

Shasun Pharmaceuticals Ltd and Debiopharm Group™ enter into licensing agreement for the manufacturing and commercialization of Huperzine-A

Debiopharm Group participates in first round of financing for compliant concept, an Empa and ETH Zurich spin-off bound for success…

Spinomix closes a $ 3 Million financing round led by Debiopharm Group™

Chugai and Debiopharm Group Announce an Exclusive License Agreement for Anti-Cancer Agent, FF284 (Debio 1347)